2015 APhA-ASP Reference Committee Report

The APhA-ASP Reference Committee met in closed session from 6:10pm – 6:50pm on Saturday, March 28, 2015. The members of the 2015 APhA-ASP Reference Committee are as follows:

Chair: Loren Kirk, 2014-2015 APhA-ASP Speaker of the House

Region 1: Nancy Moua, University of New England
Region 2: Elissa Lechtenstein, University of Maryland
Region 3: Monroe Crawley, University of Tennessee
Region 4: Ian Dilley, Purdue University
Region 5: Morgan Pusek, Creighton University
Region 6: Natalie Weltman, University of North Texas System
Region 7: Jenner Minto, University of Montana
Region 8: Vahe Lepedjian, Midwestern University - Glendale

2015 Reference Committee Recommendations

The APhA-ASP Reference Committee considered the testimony presented during the APhA-ASP Open Hearing on Proposed Resolutions on the Report of the 2015 APhA-ASP Resolutions Committee.

2015.1 – Medication Synchronization
1. APhA-ASP supports stakeholders’ implementation of medication synchronization as a standard of practice.
   *The Reference Committee recommends to ADOPT Issue 2015.1.1 of the Committee Report, and I so move.*

2015.1 – Medication Synchronization
2. APhA-ASP supports state and federal legislation encouraging third-party payers to cover the alignment of refills without the patient incurring additional out of pocket expenses.
   *The Reference Committee recommends to ADOPT Issue 2015.1.2 of the Committee Report, and I so move.*

2015.1 – Medication Synchronization
3. APhA-ASP encourages pharmacists and student pharmacists to provide education to all health care providers regarding medication synchronization.
   *The Reference Committee recommends to ADOPT Issue 2015.1.3 of the Committee Report, and I so move.*

2015.1 – Medication Synchronization
4. APhA-ASP encourages pharmacists and student pharmacists to promote patient awareness of the benefits and accessibility of medication synchronization programs.
   *The Reference Committee recommends to ADOPT Issue 2015.1.4 of the Committee Report, and I so move.*

2015.1 – Medication Synchronization
5. APhA-ASP encourages all schools and colleges of pharmacy to incorporate medication synchronization education in the curriculum.
   *The Reference Committee recommends to ADOPT Issue 2015.1.5 of the Committee Report, and I so move.*

2015.2 – Labeling and Measurement of Oral Liquid Medications
1. APhA-ASP supports mandatory inclusion of a precision measuring device, such as an oral syringe, with all prescription and non-prescription oral liquid medications.
   *The Reference Committee recommends to ADOPT Issue 2015.2.1 of the Committee Report, and I so move.*

2015.2 – Labeling and Measurement of Oral Liquid Medications
2. APhA-ASP encourages student pharmacists and pharmacists to educate patients and caregivers on accurate oral liquid medication administration.
   *The Reference Committee recommends to ADOPT Issue 2015.2.2 of the Committee Report, and I so move.*
2015.2 – Labeling and Measurement of Oral Liquid Medications
3. APhA-ASP supports the use of milliliters **metric units** (versus teaspoons and tablespoons) as the standard unit of measurement on all oral liquid medications and precision measuring devices.

*The Reference Committee recommends to ADOPT AS AMENDED Issue 2015.2.3 of the Committee Report, and I so move.*

2015.3 – Point of Care Testing
1. APhA-ASP supports state and federal legislation that allows pharmacists and student pharmacists to provide point of care tests and related clinical services—under appropriate protocol and in collaboration with other members of the health care team—to increase patient access to care and screen or monitor for indications requiring care follow-up, referral, or therapy adjustment. Point of care testing and related clinical services such as subsequent referral, counseling and/or other interventions may include, but not be limited to, HIV, influenza, streptococcal and tuberculosis screenings.

*The Reference Committee recommends to ADOPT Issue 2015.3.1 of the Committee Report, and I so move.*

2015.3 – Point of Care Testing
2. APhA-ASP supports the incorporation of point of care testing education and training throughout the pharmacy curriculum to train student pharmacists on appropriate administration of tests and management of results, including but not limited to, relevant counseling, documentation, reporting, and follow-up.

*The Reference Committee recommends to ADOPT Issue 2015.3.2 of the Committee Report, and I so move.*

2015.3 – Point of Care Testing
3. APhA-ASP encourages the development of continuing education and training programs to enhance existing practitioner understanding and utilization of point of care testing.

*The Reference Committee recommends to ADOPT Issue 2015.3.3 of the Committee Report, and I so move.*

2015.3 – Point of Care Testing
4. APhA-ASP encourages all stakeholders, including but not limited to, employers, patients, pharmacists, community pharmacies, health-systems, and third party payers to develop a compensation model recognizing the value and cost of pharmacist–provided point of care testing and the provision of related clinical services that is both financially viable and in the best interest of patients.

*The Reference Committee recommends to ADOPT Issue 2015.3.4 of the Committee Report, and I so move.*

2015.3 – Point of Care Testing
5. APhA-ASP encourages all public health stakeholders and agencies to promote patient awareness of pharmacist–provided point of care testing and related clinical services for the purpose of improving community surveillance of disease prevalence and incidence.

*The Reference Committee recommends to ADOPT AS AMENDED Issue 2015.3.5 of the Committee Report, and I so move.*

2015.4 – Increased Access to Opioid Reversal Agents
1. APhA-ASP supports state and federal legislation to increase access to opioid reversal agents.

*The Reference Committee recommends to ADOPT Issue 2015.4.1 of the Committee Report, and I so move.*

2015.4 – Increased Access to Opioid Reversal Agents
2. APhA-ASP encourages pharmacists and student pharmacists to provide public education about opioid reversal agents, including proper administration in situations of opioid-related drug overdose.

*The Reference Committee recommends to ADOPT Issue 2015.4.2 of the Committee Report, and I so move.*

**2015 APhA-ASP NEW BUSINESS REVIEW COMMITTEE REPORT**

The APhA-ASP New Business Review Committee did not meeting during the APhA2015 Annual Meeting & Exposition. No New Business Items were submitted prior to the Open Hearing on New Business.